A Phase 3 interventional study of Vamikibart and Sham in Uveitic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 77 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 14 in phase 3, and was the 21st registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 14 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 377 across the 25 interventional studies, 736 across the 3 observational. Of the 23 that completed or were terminated, 17 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Macular Edema by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 4 high-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.
Drug: Vamikibart
Participants will receive 4 low-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.
Drug: Vamikibart
Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.
Other: Sham
Participants will receive vamikibart IVT injection
Also known as: RO7200220
Participants will receive a sham procedure that mimics an IVT injection.
Proportion of participants with ≥ 15 letter improvement from baseline in best-corrected visual acuity (BCVA) at Week 16
Time frame: Week 16
Proportion of participants with ≥ 15 letter improvement from baseline in BCVA at Week 20
Time frame: Week 20
Change from baseline in BCVA at Week 16
Time frame: Week 16
Change from baseline in central subfield thickness (CST) at Week 16
Time frame: Week 16
Change from Baseline in BCVA at Weeks 20 and 52
Time frame: Weeks 20 and 52
Change from baseline in CST at Weeks 20 and 52
Time frame: Weeks 20 and 52
Proportion of participants with uveitic macular edema secondary to non-infectious uveitis (UME) resolution defined by standardized (by machine) CST threshold <325um on optical coherence tomography (OCT) from baseline at Weeks 16 and 52
Time frame: Weeks 16 and 52
Time to rescue treatment
Time frame: Up to Week 52
Number of rescue treatments received
Time frame: Up to Week 52
Type of rescue treatments received
Time frame: Up to Week 52
Proportion of participants with ≥15 letter improvement from baseline in BCVA at Week 16 and 52
Time frame: Weeks 16 and 52
Proportion of participants without ≥15 letter loss from baseline in BCVA at Week 16 and 52
Time frame: Weeks 16 and 52
Number of PRN injections received
Time frame: Up to Week 52
Time to first PRN injection
Time frame: Up to Week 52
Change from baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) at Weeks 16 and 52
Time frame: Weeks 16 and 52
Percentage of participants with ocular adverse events (AEs)
Time frame: Up to Week 52
Percentage of participants with non-ocular AEs
Time frame: Up to Week 52
Percent change from baseline in corneal endothelial cell density at Week 24
Time frame: Week 24
Percentage of participants with adverse events of special interest (AESIs)
Time frame: Up to Week 52
Percent change from baseline in corneal endothelial cell density at Week 52
Time frame: Week 52
Aqueous humor (AH) concentration of vamikibart
Time frame: Up to Week 52
Serum concentration of vamikibart
Time frame: Up to Week 52
Anti-drug antibody titer to vamikibart
Time frame: Baseline to Week 52
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Dec 2024, 23 months.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 23 months is close to that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vamikibart